Survodutide Phase 3 Data Signal Metabolic Gains Beyond Weight Loss

Survodutide, the dual glucagon/glucagon-like peptide-1 (GLP-1) receptor agonist already drawing attention for its weight loss profile, has now demonstrated what investigators describe as targeted, organ-specific reductions in visceral and liver fat. These are findings with pthe potentialto reframe how clinicians and payers evaluate efficacy in obesity pharmacotherapy, according to phase 3 data presented at the American Diabetes Association 2026 Scientific Sessions and simultaneously published in the New England Journal of Medicine.^1-6

Phase 3 results from the SYNCHRONIZE-1 (NCT06066515) and SYNCHRONIZE-MASLD (NCT06309992) trials showed that survodutide (Boehringer Ingelheim) produced meaningful reductions in liver fat content and visceral adiposity that appeared disproportionate to overall weight loss, a signal that the drug’s dual mechanism may confer metabolic benefits independent of pounds shed. The findings arrive as payers, health systems, and policy makers increasingly grapple with how to define and measure clinical value in the rapidly expanding market for obesity medications.

What the SYNCHRONIZE-1 Phase 3 Data Revealed^3,6,7

SYNCHRONIZE-1 was a 76-week, phase 3, double-blind, randomized, placebo-controlled trial that enrolled 725 adults with a body mass index (BMI) of 30 or greater, or 27 or greater with at least 1 obesity-related complication, excluding type 2 diabetes. Participants were randomized 1:1:1 to receive once-weekly subcutaneous survodutide adjusted up to 3.6 mg (n = 241) or 6.0 mg (n = 242), or placebo (n = 242), alongside counseling for reduced-calorie diet and increased physical activity. The trial was conducted across 116 clinical sites in 14 countries between November 2023 and February 2026.

At week 76, the mean change in body weight under the treatment-regimen estimand, which accounts for early discontinuations and protocol deviations, was −12.2% in the 3.6-mg group and −13.0% in the 6.0-mg group vs −5.4% in the placebo group (P < .001 for both comparisons). Under the efficacy estimand, which models the effect of full protocol adherence, weight reductions reached −15.3% and −16.6%, respectively, vs −3.2% with placebo. Overall, 72.6% and 71.9% of survodutide-treated participants achieved at least 5% body weight reduction at week 76 vs 46.3% with placebo; 28.5% of those on the 6.0-mg dose achieved at least 20% weight reduction vs 6.6% on placebo.

Baseline characteristics were notable: the mean BMI was 37.9, the mean body weight was 108.8 kg, and nearly 70% of participants had at least 1 obesity-related complication, most commonly hypertension (40.1%), dyslipidemia (33.9%), and obstructive sleep apnea (18.3%). Females achieved substantially greater weight loss than males, at approximately 19.5% vs 12.6% at the 6.0-mg dose in clinical discussions of the data, a sex-differential pattern seen across the GLP-1 receptor agonist class.⁵

How Liver and Visceral Fat Results Set Survodutide Apart^3,6

One of the more clinically striking findings from SYNCHRONIZE-1 emerged from a prespecified magnetic resonance imaging (MRI) substudy of 25 participants per arm. At the 6.0-mg dose, survodutide was associated with a 63.1% relative reduction in liver fat content from baseline to week 76 compared with 24.5% in the placebo group. Visceral fat volume fell by 34.0% with the higher survodutide dose vs 11.8% with placebo, while lean body volume declined by only 9.8%, meaning that more than 89% of total tissue change was fat mass, not lean mass.

Lee Kaplan, MD, PhD, director of The Obesity and Metabolism Institute at Massachusetts General Hospital and chair of the SYNCHRONIZE program executive committee, noted that the liver fat reductions appeared earlier in treatment than would be expected from weight loss alone and were more pronounced at the 6.0-mg dose despite similar weight reductions across doses.⁸ This dose-fat dissociation, he argued, suggests a mechanism beyond caloric restriction: glucagon receptor agonism is thought to act directly on hepatic tissue to reduce lipid accumulation, resolve inflammation, and improve fibrosis markers, independent of overall body weight trajectory.^5,8

“What we’re seeing is something that is specific to the treatment and is specific to the liver more than it is just an association with the amount of weight loss,” Kaplan stated in an interview with The American Journal of Managed Care^®.⁸ The observation carries clinical weight, he explained: excess visceral adiposity and hepatic fat are key drivers of metabolic dysfunction, closely linked to systemic inflammation, impaired insulin sensitivity, and progression to metabolic dysfunction–associated steatohepatitis (MASH).

The science underlying survodutide’s dual mechanism traces back more than 2 decades. In the early 2000s, researchers including Matthias Tschöp, MD, Ludwig Maximilian University of Munich, began exploring oxyntomodulin, an endogenous incretin-related peptide hormone that stimulates both the glucagon and GLP-1 receptors, as a template for engineered compounds that could reduce food intake, increase energy expenditure, and directly modulate hepatic lipid metabolism.¹ Early work in rodent and primate models demonstrated that combined glucagon/GLP-1 receptor activation achieved greater fat loss than GLP-1 agonism alone, without the hyperglycemic liability of pure glucagon agonism. Survodutide (also known as BI 456906) was developed from that mechanistic lineage.

“Glucagon can drive energy expenditure. It can help with burning calories, thermogenesis, metabolism, maybe even contribute to satiation,” Tschöp said, “so it’s a good thing if you want to have that in your polyagonist approach to obesity.”

SYNCHRONIZE-MASLD: Liver Normalization in 6 of 10 Patients^3,4,7,9

A parallel 48-week phase 3 trial, SYNCHRONIZE-MASLD, provided more direct evidence of survodutide’s hepatic potential. The trial enrolled 218 adults with obesity or overweight and metabolic dysfunction–associated steatotic liver disease (MASLD), defined by hepatic steatosis with evidence of inflammation and/or fibrosis, both with and without type 2 diabetes. Participants received survodutide 6.0 mg or placebo in a 2:1 randomization.

The trial met both co-primary end points. Under the efficacy estimand, up to 84.2% of survodutide-treated participants achieved at least a 30% relative liver fat reduction from baseline to week 48 compared with 24.3% on placebo (P < .0001). Body weight declined by up to 12.2% with survodutide vs 1.0% with placebo. Critically, a prespecified secondary end point found that 61.0% of treated participants achieved liver fat normalization, defined as liver fat content below 5% by MRI-measured proton density fat fraction vs 5.7% with placebo.

Kaplan placed those numbers in clinical context: a 30% reduction in liver fat has been associated in the literature with improvement in MASH activity, while a 50% reduction has been linked to improvements in fibrosis stage. The reductions observed in SYNCHRONIZE-MASLD exceed both thresholds, suggesting the potential for meaningful disease modification in patients at elevated risk for hepatic progression.

The study population reflected the real-world complexity of MASLD comorbidity: average age 55, BMI 39.6, and 38.4% with type 2 diabetes. Liver fat at baseline averaged 16.9% by MRI-measured proton density fat fraction, and moderate liver stiffness was present on FibroScan assessments. Improvements in alanine transaminase levels, a liver inflammation biomarker, were observed as a secondary end point, consistent with the drug’s proposed anti-inflammatory hepatic mechanism.

Safety Profile and Tolerability Considerations^3,6

The safety profile of survodutide across both trials was broadly consistent with the GLP-1 receptor agonist class. Gastrointestinal (GI) adverse events, primarily nausea, vomiting, diarrhea, and constipation, were more frequent with survodutide than placebo and occurred most commonly during dose escalation. In SYNCHRONIZE-1, GI events led to treatment discontinuation in 17.8% of participants in the 3.6-mg group and 20.2% in the 6.0-mg group vs 2.9% with placebo.

No deaths were reported, and no adjudication-confirmed cases of major adverse cardiovascular events occurred in the survodutide arms; one ischemic stroke was confirmed in the placebo group. There were no confirmed cases of pancreatic cancer, thyroid cancer, or acute pancreatitis. Asymptomatic pancreatic hyperenzymemia was slightly more common in the survodutide groups. A modest increase in heart rate of 3.2 to 3.5 beats per minute was noted at week 76, consistent with the known pharmacodynamic effects of the drug class.

A key limitation of SYNCHRONIZE-1 was the unexpectedly high weight loss in the placebo group, at 5.4% vs the 2% to 3% assumed in the power calculation, which investigators attributed in part to substantial crossover use of GLP-1 receptor agonist medications among participants who discontinued placebo. More than 16% of the placebo group reported using a prohibited GLP-1-based medication while still enrolled in the trial, a reflection of the rapidly widening commercial availability of obesity pharmacotherapies during the trial period.

Ania Jastreboff, MD, PhD, professor of medicine and director of the Yale Obesity Research Center, who presented on the rationale and design of the SYNCHRONIZE trials, noted, “It’s becoming increasingly challenging to keep participants on treatment, given that they seek out other forms of treatment when they realize they are not losing weight.”

Lead investigator Carel le Roux, MBChB, FRCP, FRCPath, PhD, University College Dublin, drew the broader implication: "We are getting into a space now where it’s becoming harder and harder for us to run drug against placebo,” he said. “What we are seeing now more and more is that we’re going to run drug against usual care.” This real-world complication of the control arm has direct implications for how managed care stakeholders interpret treatment-regimen vs efficacy-estimand results.

Discontinuation due to tolerability remains a meaningful clinical and economic consideration. As discussant Jaime Almandoz, MD, MBA, FTOS, UT Southwestern Medical Center, noted in his discussion of these data, premature treatment discontinuation rates of 35% to 40% in the trial underscore the need for individualized dose titration protocols and wraparound behavioral support.⁵ These are factors with direct implications for real-world treatment persistence and long-term cost-effectiveness modeling.

“What is a maintenance dose that's appropriate?” Almandoz posed. “It's not the tolerated dose, but perhaps the minimum effective dose for helping someone to achieve not just their weight, but their health goals.”

What This Means for Managed Care and Clinical Practice

The SYNCHRONIZE program data arrive at a pivotal moment for obesity policy in the US. Payers and pharmacy benefit managers are grappling with coverage decisions for an expanding portfolio of injectable weight-loss agents, decisions that increasingly hinge not just on weight reduction magnitude but on demonstrated improvements in cardiometabolic risk factors, organ-specific outcomes, and long-term complications.

The obesity pharmacotherapy landscape is evolving rapidly, causing managed care organizations to weigh the cost of newer agents against the long-term burden of obesity-related complications, including cardiovascular disease, type 2 diabetes, and liver disease, Kaplan explained.⁸ Survodutide has received FDA Fast Track designation and Breakthrough Therapy designation for the treatment of adults with MASH and fibrosis, as well as recognition from the European Medicines Agency under its Priority Medicine (PRIME) scheme, regulatory signals that reflect the unmet need in a space where few approved disease-modifying options exist.⁷

Results from SYNCHRONIZE-2 (NCT06066528), evaluating survodutide in adults with type 2 diabetes and obesity, are expected later in 2026.⁷ The ongoing SYNCHRONIZE-CVOT trial (NCT06077864) is designed to provide cardiovascular outcomes data. Additional phase 3b studies, including ELEVATE-LIVER, which will assess survodutide's impact on cardiac structure and function in people with MASLD or early MASH, and SYNCHRONIZE-START, examining real-world titration approaches and switching from GLP-1 receptor agonists, are expected to generate the implementation-level evidence that payers and health systems will need to inform formulary and care pathway decisions.

Survodutide remains an investigational agent; its efficacy and safety have not been established by a regulatory body, and it is not yet approved for use in any market.

References

1. Tschöp MH. Gut hormone receptor poly-agonists: discovery and clinical validation. Presented at: American Diabetes Association 2026 Scientific Sessions; June 5-8, 2026; New Orleans, LA.
2. Jastreboff A. Rationale and design of the SYNCHRONIZE phase 3 studies for the treatment of obesity. Presented at: American Diabetes Association 2026 Scientific Sessions; June 5-8, 2026; New Orleans, LA.
3. le Roux CW. Efficacy and safety of survodutide for the treatment of obesity in people without diabetes: results from SYNCHRONIZE-1 (NCT06066515). Presented at: American Diabetes Association 2026 Scientific Sessions; June 5-8, 2026; New Orleans, LA.
4. Kaplan L. Design and outcomes of SYNCHRONIZE-MASLD: survodutide for the treatment of obesity and MASLD (NCT06309992). Presented at: American Diabetes Association 2026 Scientific Sessions; June 5-8, 2026; New Orleans, LA.
5. Almandoz J. The clinical implications of glucagon/GLP-1 receptor dual activation for the treatment of obesity and steatotic liver disease. Presented at: American Diabetes Association 2026 Scientific Sessions; June 5-8, 2026; New Orleans, LA.
6. le Roux CW, Wharton S, Startseva E, et al. Survodutide once weekly for the treatment of adults with obesity. N Engl J Med. Published online June 7, 2026. doi:10.1056/NEJMoa2600751
7. Boehringer Ingelheim’s survodutide phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, supporting improved metabolic health in people living with obesity. News release. Boehringer Ingelheim. June 7, 2026. Accessed June 8, 2026. https://www.boehringer-ingelheim.com/human-health/metabolic-diseases/survodutide-phase-3-fat-loss-obesity-dual-agonist-data
8. Grossi G, Kaplan LM. Emerging data suggest survodutide targets liver fat more rapidly than weight loss: Lee Kaplan, MD, PhD. AJMC^®. June 7, 2026. Accessed June 8, 2026. https://www.ajmc.com/view/emerging-data-suggest-survodutide-targets-liver-fat-more-rapidly-than-weight-loss-lee-kaplan-md-phd
9. Grossi G, Kaplan LM. Survodutide normalizes liver fat in 61% of patients with MASLD in phase 3 trial: Lee Kaplan, MD, PhD. AJMC. June 7, 2026. Accessed June 8, 2026. https://www.ajmc.com/view/survodutide-normalizes-liver-fat-in-61-of-patients-with-masld-in-phase-3-trial-lee-kaplan-md-phd